Novel Emblica officinalis extract containing β-glucogallin vs. metformin: a randomized, open-label, comparative efficacy study in newly diagnosed type 2 diabetes mellitus patients with dyslipidemia.
What this study found
Emblica officinalis extract improved glycemic control and lipid parameters, with the 2 g/day dose performing best overall. In the EOE 2 g/day arm, HbA1c fell from 7.90 ± 0.81% to 6.87 ± 0.67%, and reductions in fasting glucose, postprandial glucose, triglycerides, total cholesterol, and LDL were all significant within groups (p < 0.01). Fasting glucose declined from 140.24 ± 4.57 to 109.69 ± 16.38 mg/dL, and postprandial glucose from 245.31 ± 22.71 to 205.57 ± 20.15 mg/dL. The 2 g/day dose produced greater HbA1c and lipid improvements than the 1 g/day dose and metformin, while the 1 g/day…
- Study & population
- This was a three-arm, randomized, open-label, multicenter comparative study conducted in India.
- Intervention
- Emblica officinalis extract standardized to 10% beta-glucogallin was given orally for 90 days.
- Key limitation
- The trial was open-label and short term, with only 90 days of follow-up.
View source
Open PDFOriginal abstract
The efficacy of Emblica officinalis extract (EOE) containing 10% β-glucogallin was compared against metformin in newly diagnosed subjects with diabetic dyslipidemia which is a significant factor in cardiovascular disease. Daily administration with EOE-1 g, EOE-2 g, or metformin 500 mg for 90 days significantly decreased fasting blood sugar and postprandial blood sugar (FBS and PPBS), hemoglobin A1c (HbA1c) and lipid levels in all three treatment groups. The FBS, PPBS and HbA1c were significantly lower in the EOE-2 g group compared with metformin and EOE-1 g groups. The reductions in LDL and TC in the EOE-2 g group were also significantly higher than in the EOE-1 g group and were comparable to the metformin group. No serious adverse effects were observed in any study participants. EOE-1 g and 2 g day-1 are safe and potent antidiabetic agents, with comparable efficacy to the pharmaceutical drug, metformin. Supplementation with EOE-2 g day-1 showed greater efficacy than metformin in reducing circulating glucose levels.